{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:47:06Z","timestamp":1787827626311,"version":"build-2784847793"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jneuroim.2026.578930","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:21:20Z","timestamp":1775578880000},"page":"578930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Re-challenge of immune checkpoint inhibitor after ICI-encephalitis: A case report"],"prefix":"10.1016","volume":"417","author":[{"given":"Virginia","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suma","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jneuroim.2026.578930_bb0005","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/14737140.2025.2517274","article-title":"Immune checkpoint inhibitor resumption after discontinuation due to immune-related adverse events: a nomogram-based analysis of risk factors and outcomes","volume":"25","author":"Acar","year":"2025","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"2","key":"10.1016\/j.jneuroim.2026.578930_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001622","article-title":"Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade \u22652 immune-related adverse events in patients with cancer","volume":"8","author":"Allouchery","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.jneuroim.2026.578930_bb0015","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3390\/cancers14040955","article-title":"Safety of immune checkpoint inhibitor resumption after interruption for immune-related adverse events, a narrative review","volume":"14","author":"Allouchery","year":"2022","journal-title":"Cancers"},{"issue":"17","key":"10.1016\/j.jneuroim.2026.578930_bb0020","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jneuroim.2026.578930_bb0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/jns.12371","article-title":"Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: experience beyond the clinical trials","volume":"25","author":"Bruna","year":"2020","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jneuroim.2026.578930_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.jneuroim.2026.578930_bb0035","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.jneuroim.2026.578930_bb0040","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.578930_bb0045","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2026.578930_bb0050","article-title":"Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study","volume":"44","author":"Farina","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"3","key":"10.1016\/j.jneuroim.2026.578930_bb0055","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"137","author":"Fellner","year":"2018","journal-title":"J. Neurooncol"},{"issue":"1","key":"10.1016\/j.jneuroim.2026.578930_bb0060","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"7","key":"10.1016\/j.jneuroim.2026.578930_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"suppl_4","key":"10.1016\/j.jneuroim.2026.578930_bb0070","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.jneuroim.2026.578930_bb0075","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jneuroim.2026.578930_bb0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","article-title":"Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database","volume":"152","author":"Mikami","year":"2021","journal-title":"J. Neurooncol"},{"issue":"4","key":"10.1016\/j.jneuroim.2026.578930_bb0085","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature","volume":"24","author":"Reynolds","year":"2019","journal-title":"Oncologist"},{"issue":"6382","key":"10.1016\/j.jneuroim.2026.578930_bb0090","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2026.578930_bb0095","article-title":"Nivolumab-induced autoimmune encephalitis in two patients with lung adenocarcinoma","volume":"2018","author":"Shah","year":"2018","journal-title":"Case Rep. Neurol. Med."},{"issue":"3","key":"10.1016\/j.jneuroim.2026.578930_bb0100","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of Immunotherapy-Related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"7","key":"10.1016\/j.jneuroim.2026.578930_bb0105","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2026.578930_bb0110","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jneuroim.2026.578930_bb0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/NRL.0000000000000230","article-title":"Risk of neurological toxicities following the use of different immune checkpoint inhibitor regimens in solid tumors: a systematic review and meta-analysis","volume":"24","author":"Xu","year":"2019","journal-title":"Neurologist"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826000780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826000780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:53:35Z","timestamp":1784552015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572826000780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":23,"alternative-id":["S0165572826000780"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.578930","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-challenge of immune checkpoint inhibitor after ICI-encephalitis: A case report","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.578930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"578930"}}